About: ADB-FUBINACA     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : dbo:Drug, within Data Space : dbpedia.org associated with source document(s)
QRcode icon
http://dbpedia.org/describe/?url=http%3A%2F%2Fdbpedia.org%2Fresource%2FADB-FUBINACA

ADB-FUBINACA is a designer drug identified in synthetic cannabis blends in Japan in 2013. In 2018, it was the third-most common synthetic cannabinoid identified in drugs seized by the Drug Enforcement Administration. An analogue of ADB-FUBINACA, ADSB-FUB-187, containing a more functionalized carboxamide substituent was recently reported.

AttributesValues
rdf:type
rdfs:label
  • ADB-FUBINACA (en)
rdfs:comment
  • ADB-FUBINACA is a designer drug identified in synthetic cannabis blends in Japan in 2013. In 2018, it was the third-most common synthetic cannabinoid identified in drugs seized by the Drug Enforcement Administration. An analogue of ADB-FUBINACA, ADSB-FUB-187, containing a more functionalized carboxamide substituent was recently reported. (en)
foaf:depiction
  • http://commons.wikimedia.org/wiki/Special:FilePath/ADB-FUBINACA_structure.png
dcterms:subject
Wikipage page ID
Wikipage revision ID
Link from a Wikipage to another Wikipage
sameAs
dbp:wikiPageUsesTemplate
thumbnail
c
CAS number
ChemSpiderID
F
H
IUPAC name
  • N--1--1H-indazole-3-carboxamide (en)
legal DE
  • Anlage II (en)
legal UK
  • Class B (en)
legal US
  • Schedule I (en)
n
O
PubChem
SMILES
  • O=CC1=NNC3=C1C=CC=C3 (en)
StdInChI
  • InChI=1S/C21H23FN4O2/c1-211824-2017-15-6-4-5-7-162612-13-8-10-1411-9-13/h4-11,18H,12H2,1-3H3,/t18-/m1/s1 (en)
StdInChIKey
  • ZSSGCSINPVBLQD-GOSISDBHSA-N (en)
UNII
has abstract
  • ADB-FUBINACA is a designer drug identified in synthetic cannabis blends in Japan in 2013. In 2018, it was the third-most common synthetic cannabinoid identified in drugs seized by the Drug Enforcement Administration. The (S)-enantiomer of ADB-FUBINACA is described in a 2009 Pfizer patent and has been reported to be a potent agonist of the CB1 receptor and the CB2 receptor with EC50 values of 1.2 nM and 3.5 nM, respectively. ADB-FUBINACA features a carboxamide group at the 3-indazole position, like SDB-001 and STS-135. ADB-FUBINACA appears to be the product of rational drug design, since it differs from AB-FUBINACA only by the replacement of the isopropyl group with a tert-butyl group. An analogue of ADB-FUBINACA, ADSB-FUB-187, containing a more functionalized carboxamide substituent was recently reported. (en)
legal CA
  • Schedule II (en)
gold:hypernym
prov:wasDerivedFrom
page length (characters) of wiki page
CAS number
  • 1185282-00-1
FDA UNII code
  • 05235E1S2O
PubChem
  • 70969086
foaf:isPrimaryTopicOf
is Link from a Wikipage to another Wikipage of
Faceted Search & Find service v1.17_git139 as of Feb 29 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 08.03.3330 as of Mar 19 2024, on Linux (x86_64-generic-linux-glibc212), Single-Server Edition (61 GB total memory, 44 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software